SV

Street Verdict

Analyst Scorecard

A record of what Nischal Maheshwari said publicly, with the source. Not advice.

“Within the pharmaceutical sector, Nischal Maheshwari favors the CDMO sub-segment, which he sees growing very rapidly. Laurus Labs is his top pick in this space, and he holds it in his portfolio.”
Laurus Labs LimitedBullishCalled 13 Jan 2026Graded 13 Apr 2026
Verdict:HIT

How this relative call is judged

A relative call is a comparison, judged on closing prices from the first close after the call to the end of its window (3 months when the quote states no time frame). The spread is the pick's return minus the comparator's return: above zero is a hit for a call that favours the pick, and the reverse for a call that marks it down.

Compared with: Nifty Pharma.

Window: 90 days from the call.

The pick -0.25%, Nifty Pharma -1.80%: spread +1.55 points. The spread went the way the call said. Hit.

The grader’s working: R6 RELATIVE (BULLISH vs Nifty Pharma): pick entered ₹1090.5 on 2026-01-14, Nifty Pharma entered ₹22505.4 on 2026-01-14; to 2026-04-13: pick -0.25% vs Nifty Pharma -1.80%, spread +1.55 points -> HIT (a spread above zero is a hit). No time frame stated: a relative call is judged over 3 months (90 days) from publication. Read from the quote: top pick against "Nifty Pharma".

Read the original articleSee Nischal Maheshwari’s full track record